FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947568608> ?p ?o ?g. }

• W2947568608 abstract "The optimal treatment algorithm for iron therapy and the use of erythropoiesis-stimulating agents (ESA) in anemic hemodialysis (HD) patients has not been established. Hemoglobin (Hb) target levels can be achieved through more frequent intravenous (IV) iron use with lower ESA dose, or with less iron dosing but higher ESA. ESA therapy to correct anemia may result in severe arterial and venous thrombotic complications and the evidence base evaluating hard clinical outcomes related to the use of IV iron is sparse. A total of 1247 maintenance HD patients from 12 dialysis centers in Portugal (n = 730) and Poland (n = 517) were considered. We assessed achievement of KDIGO renal anemia targets with focus on treatment strategies, which typically differ between countries. In Poland the use and dose of IV iron was 35–72% higher than that in Portugal (p < 0.001) during three consecutive months; use and dose of ESA was 61% higher in Portugal (5034 vs 3133 IU (adjusted)/week, p < 0.001). Mean Hb concentration was similar (11.0 vs 11.0 g/dL) in patients treated in both countries and the proportion of patients within KDIGO anemia target was 69.5% in Poland vs 65.8% in Portugal (NS). Ferritin and TSAT levels and the proportion of patients with TSAT > 20 and > 50% were both significantly higher in patients in Poland (88.8 and 14.6%) than in Portugal (76.3 and 5.7% respectively, p < 0.001). Significantly more patients in Poland had a ferritin concentration > 800 μg/L (35.6%) compared to Portugal (15.8%, p < 0.001). The ESA resistance index (ERI) was significantly higher in patients treated in Portugal (p < 0.001). Correlation analyses showed confounding by treatment indication in unadjusted models. Multiple and logistic regression analyses showed that with ferritin within KDIGO recommended range of 200–800 μg/L the odds for Hb within guidelines increased significantly. Annual gross mortality was 16% in Poland and 13% in Portugal (NS); there were no differences in cause-specific mortality. Administration of high doses of IV iron in routine clinical HD practice may not be associated with considerable harm. However, large randomized controlled trials are needed to provide absolute evidence of iron safety." @default.
• W2947568608 created "2019-06-07" @default.
• W2947568608 creator A5003423371 @default.
• W2947568608 creator A5003642015 @default.
• W2947568608 creator A5011902363 @default.
• W2947568608 creator A5020118076 @default.
• W2947568608 creator A5021209413 @default.
• W2947568608 creator A5034168251 @default.
• W2947568608 creator A5042020693 @default.
• W2947568608 creator A5067688896 @default.
• W2947568608 creator A5071996347 @default.
• W2947568608 creator A5081309578 @default.
• W2947568608 date "2019-01-07" @default.
• W2947568608 modified "2023-10-08" @default.
• W2947568608 title "Achievement of renal anemia KDIGO targets by two different clinical strategies – a European hemodialysis multicenter analysis" @default.
• W2947568608 cites W1877140995 @default.
• W2947568608 cites W1966959314 @default.
• W2947568608 cites W1998943227 @default.
• W2947568608 cites W2000924380 @default.
• W2947568608 cites W2001308749 @default.
• W2947568608 cites W2005973637 @default.
• W2947568608 cites W2008019120 @default.
• W2947568608 cites W2009192569 @default.
• W2947568608 cites W2010494541 @default.
• W2947568608 cites W2023335720 @default.
• W2947568608 cites W2033803279 @default.
• W2947568608 cites W2040029744 @default.
• W2947568608 cites W2056969309 @default.
• W2947568608 cites W2059698794 @default.
• W2947568608 cites W2079130638 @default.
• W2947568608 cites W2088030171 @default.
• W2947568608 cites W2111249486 @default.
• W2947568608 cites W2132170119 @default.
• W2947568608 cites W2132989103 @default.
• W2947568608 cites W2134487085 @default.
• W2947568608 cites W2135454486 @default.
• W2947568608 cites W2138222693 @default.
• W2947568608 cites W2146368274 @default.
• W2947568608 cites W2156895183 @default.
• W2947568608 cites W2164442951 @default.
• W2947568608 cites W2373077024 @default.
• W2947568608 cites W2507214598 @default.
• W2947568608 cites W2580449060 @default.
• W2947568608 cites W2584947097 @default.
• W2947568608 cites W2596955988 @default.
• W2947568608 cites W2735919568 @default.
• W2947568608 cites W2752587056 @default.
• W2947568608 cites W2766777562 @default.
• W2947568608 cites W2788067661 @default.
• W2947568608 cites W4232269465 @default.
• W2947568608 cites W3149132779 @default.
• W2947568608 doi "https://doi.org/10.1186/s12882-018-1196-7" @default.
• W2947568608 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6323791" @default.
• W2947568608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30616548" @default.
• W2947568608 hasPublicationYear "2019" @default.
• W2947568608 type Work @default.
• W2947568608 sameAs 2947568608 @default.
• W2947568608 citedByCount "6" @default.
• W2947568608 countsByYear W29475686082019 @default.
• W2947568608 countsByYear W29475686082021 @default.
• W2947568608 countsByYear W29475686082023 @default.
• W2947568608 crossrefType "journal-article" @default.
• W2947568608 hasAuthorship W2947568608A5003423371 @default.
• W2947568608 hasAuthorship W2947568608A5003642015 @default.
• W2947568608 hasAuthorship W2947568608A5011902363 @default.
• W2947568608 hasAuthorship W2947568608A5020118076 @default.
• W2947568608 hasAuthorship W2947568608A5021209413 @default.
• W2947568608 hasAuthorship W2947568608A5034168251 @default.
• W2947568608 hasAuthorship W2947568608A5042020693 @default.
• W2947568608 hasAuthorship W2947568608A5067688896 @default.
• W2947568608 hasAuthorship W2947568608A5071996347 @default.
• W2947568608 hasAuthorship W2947568608A5081309578 @default.
• W2947568608 hasBestOaLocation W29475686081 @default.
• W2947568608 hasConcept C126322002 @default.
• W2947568608 hasConcept C141071460 @default.
• W2947568608 hasConcept C2777417653 @default.
• W2947568608 hasConcept C2778063415 @default.
• W2947568608 hasConcept C2778248108 @default.
• W2947568608 hasConcept C2778319317 @default.
• W2947568608 hasConcept C2778917026 @default.
• W2947568608 hasConcept C2779978075 @default.
• W2947568608 hasConcept C3019433959 @default.
• W2947568608 hasConcept C54847362 @default.
• W2947568608 hasConcept C71924100 @default.
• W2947568608 hasConcept C90924648 @default.
• W2947568608 hasConceptScore W2947568608C126322002 @default.
• W2947568608 hasConceptScore W2947568608C141071460 @default.
• W2947568608 hasConceptScore W2947568608C2777417653 @default.
• W2947568608 hasConceptScore W2947568608C2778063415 @default.
• W2947568608 hasConceptScore W2947568608C2778248108 @default.
• W2947568608 hasConceptScore W2947568608C2778319317 @default.
• W2947568608 hasConceptScore W2947568608C2778917026 @default.
• W2947568608 hasConceptScore W2947568608C2779978075 @default.
• W2947568608 hasConceptScore W2947568608C3019433959 @default.
• W2947568608 hasConceptScore W2947568608C54847362 @default.
• W2947568608 hasConceptScore W2947568608C71924100 @default.
• W2947568608 hasConceptScore W2947568608C90924648 @default.
• W2947568608 hasIssue "1" @default.
• W2947568608 hasLocation W29475686081 @default.
• W2947568608 hasLocation W29475686082 @default.

• next